Current Report Filing (8-k)
November 08 2016 - 4:38PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): November 8, 2016
AVEO Pharmaceuticals, Inc.
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
001-34655
|
|
04-3581650
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
One Broadway, 14th Floor
Cambridge, Massachusetts
|
|
02142
|
(Address of Principal Executive Offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (617) 588-1960
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (
see
General Instruction A.2. below):
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
☐
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
☐
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS:
This Form 8-K and the exhibit attached hereto contain forward-looking statements of AVEO Pharmaceuticals, Inc. (AVEO or the Company)
that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Form 8-K and the attached exhibit are forward-looking statements. The words anticipate, believe,
estimate, expect, intend, may, plan, predict, project, target, potential, will, would, could,
should, continue, contemplate, or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying
words. These forward-looking statements include, among others, statements about: AVEOs plans to leverage biomarkers and pursue strategic partnerships for certain of its assets; AVEOs goals and business strategy; the timing, design and
results of preclinical and clinical trials; the timing and outcome of meetings with and applications to regulatory authorities by AVEO and its partners; the competitive landscape for AVEOs therapeutic candidates and AVEOs estimates for
its cash runway.
Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements
AVEO makes due to a number of important factors, including substantial risks and uncertainties relating to: AVEOs ability to successfully implement its strategic plans; AVEOs ability to successfully develop, test and gain regulatory
approval of its product candidates, including its companion diagnostics; the potential safety, efficacy, tolerability and other benefits of tivozanib as a single agent or in combination with other therapies; developments, expenses and outcomes
related to AVEOs ongoing shareholder litigation; AVEOs ability to obtain necessary financing required to perform its clinical trials and achieve its other goals; AVEOs ability to establish and maintain strategic partnerships;
AVEOs ability to obtain and maintain intellectual property rights; competition; AVEOs dependence on its strategic partners and other third parties; adverse general economic and industry conditions; and those risk factors discussed in the
Risk Factors and elsewhere in AVEOs Annual Report on Form 10-K for the year ended December 31, 2015, and other periodic filings AVEO makes with the SEC. All forward-looking statements contained in this
Form 8-K
and the attached exhibit speak only as of the date of this presentation, and AVEO undertakes no obligation to update any of these statements, except as required by law. You should, therefore, not rely
on these forward-looking statements as representing the Companys views as of any date subsequent to the date of this Form 8-K.
Item 7.01.
|
Regulation FD.
|
From time to time, we conduct meetings with third parties in which we utilize a
corporate slide presentation. A copy of our current corporate slide presentation is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The presentation includes clinical, development and financial
updates. We may amend or update this information at any time and from time to time through another Current Report on Form 8-K, a later company filing, or other means.
The information in this Item 7.01 and Exhibit 99.1 shall not be deemed filed for purposes of Section 18 of the Securities Exchange Act
of 1934, as amended (the Exchange Act) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as
expressly set forth by specific reference in such a filing.
Item 9.01.
|
Financial Statements and Exhibits.
|
(d) The exhibit to this Current Report on Form 8-K is listed in the
Exhibit Index attached hereto.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
|
|
AVEO Pharmaceuticals, Inc.
|
|
Date: November 8, 2016
|
|
|
By:
|
|
/s/ Michael Bailey
|
|
|
Michael Bailey
|
|
|
President and Chief Executive Officer
|
EXHIBIT INDEX
|
|
|
Exhibit
No.
|
|
Description
|
|
|
99.1
|
|
Corporate Presentation Slide Deck dated November 8, 2016
|
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Mar 2024 to Apr 2024
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Apr 2023 to Apr 2024